Expert Perspective

Dispelling Common Headache Myths


 

Myth: It’s Not a Migraine Unless You Experience Aura

This is not true, as most migraines present without aura. Migraine with typical aura affects 30% of patients with migraine.

Myth: Researchers No Longer Investigate Migraine

False; there are several ongoing studies working to address the pathophysiology of migraine and find new treatment options. Recently, neuromodulation devices have entered the market. One such device from Theranica (called Nerivio) now has clearance from the US Food and Drug Administration for acute and preventive migraine treatment from age 12 and up. One phase 4 study by Theranica shows that Nerivio appears to be safe during pregnancy.

Several migraine studies of note include the following :

  • OnabotulinumtoxinA as a treatment for hemiplegic migraine: This project aims to evaluate the response to onabotulinumtoxinA treatments in patients with hemiplegic migraine evaluated at Mayo Clinic.

  • Occipital nerve stimulation for migraine: OPTIMISE. This study is evaluating the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine, when used in conjunction with antimigraine medications.

  • The Medication Overuse Treatment Strategy trial: This study is comparing the outcomes among patients randomized to 1 of the 2 treatment strategies for treating patients who have chronic migraine with medication overuse.

  • Metformin is being investigated as a treatment for the prevention of episodic migraine.

Myth: Migraine Cannot Be Diagnosed Without an Imaging Exam

This is false. Migraine is a clinical diagnosis and does not need any imaging to confirm. Imaging is indicated only if the symptoms are not clear or if there are neurologic symptoms or warning signs accompanying the migraine. In such cases, imaging would be warranted to rule out other pathologies. A magnetic resonance imaging scan is performed to rule out other pathology, not to diagnose migraine. A clinician must identify a pattern in the patient’s history according to the diagnostic criteria of the International Headache Society to diagnose migraine, which include that the patient had 5 previous attacks without aura or 2 attacks with aura.

Summary

Headaches, especially migraine, can be unpleasant and disabling and can significantly affect a patient’s quality of life. However, pharmaceutical and nonpharmaceutical interventions that can help are available. Lifestyle changes, including diet, sleep, and stress reduction can ease symptoms and reduce the frequency of migraine attacks. As researchers continue to investigate the pathophysiology of migraine, they are sure to identify better treatments and, perhaps one day—a cure.

Pages

Recommended Reading

Fremanezumab offers a safe and effective long-term treatment option for drug-resistant migraine
Migraine ICYMI
Galcanezumab effective for migraine prevention in women with menstrually related migraine
Migraine ICYMI
Prior onabotulinumtoxin-A improves subsequent anti-CGRP mAb response in chronic migraine
Migraine ICYMI
Comparative efficacy of anti-CGRP mAb in chronic and high-frequency episodic migraine
Migraine ICYMI
Galcanezumab and rimegepant offer effective options for prevention of episodic migraine
Migraine ICYMI
Galcanezumab and rimegepant offer effective options for prevention of episodic migraine
Migraine ICYMI
Fremanezumab benefits migraine patients with inadequate response to prior preventive medications
Migraine ICYMI
Commentary: Examining CGRP Antagonists for Migraine Relief, January 2024
Migraine ICYMI
Building a Toolkit for the Treatment of Acute Migraine
Migraine ICYMI
Retinal Perfusion Is Reduced During Migraine Attacks
Migraine ICYMI